Connect with Sona

  •  

Email: info@sonanano.com

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Home

Latest News

Sona Nanotech Engages Maxim Group for NASDAQ Listing and Investment Banking Services, and Announces Organizational Change

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (“Sona Nanotech” or the “Company”), a developer of rapid, point-of-care diagnostic tests for COVID-19 and other applications, has engaged Maxim Group, LLC (“Maxim”) for general financial advisory and investment banking services in relation … Read More

Read More

Sona Nanotech Announces Validation Results for its COVID-19 Antigen Test

July 2, 2020 – Halifax, Canada – Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company”), a developer of rapid, point-of-care diagnostic tests, is pleased to announce that its rapid detection, COVID-19 antigen test’s laboratory validation studies of performance levels … Read More

Read More

Sona Nanotech Inc. is a nanotechnology life sciences firm that has developed multiple proprietary methods for the manufacture of various types of gold nanoparticles

Sona's unique gold nanorods will power the next generation of lateral flow diagnostics

THE SONA ADVANTAGE

SonaCast - our all new podcast - is out now!
Subscribe on your favourite podcast platform.

Lateral Flow Diagnostic Applications

Food &
Beverage

Medical
Diagnostics

Environmental
Testing

Consumer Health
& Pharmaceuticals

Drugs of
Abuse

Military
Diagnostics

Animal
Diagnostics

LATERAL FLOW TEST =
IMMEDIATE PATIENT FEEDBACK

Lateral flow tests powered by Sona’s unique gold nanorods can give results within minutes.

Sona’s multi-coloured gold nanorods allow for multiple test lines per unit, with easy-to-read results  from one small sample. 

LATERAL FLOW

Advantages of Sona's Nanorod Technology

  • Allows one test to detect multiple conditions​
  • Allows one test to maximize use from a small sample
  • Allows one test to detect multiple analyses for specific conditions
  • Individual, distinct colours for quantification measurement
  • Generates amplified visual signals for simpler interpretation
  • Generates increased sensitivity, specificity & time to results
  • Sona nanorods have a longer shelf life and resistance to hot temperatures than current technology
  • Non toxic – CTAB free

Comprehensive suite of products and services for multiple applications

• Gold nanorods
• Custom conjugation
• Lateral flow test development
• Lateral flow test production

PRODUCTS & SERVICES

• Point of care diagnostics
• Drug delivery
• Photothermal therapy
• Cell imaging

APPLICATIONS

Praise for Sona's technology from businesses and academics

   “I am very optimistic about the future of Sona; the gold nanorods they make are very versatile, with huge application potential in various fields.”

Dr Shine Xu Zhang

Industrial research chair in  applied nanotechnology,  Cape Breton University

  “Gold nanorods that have been synthesized and stabilized without CTAB are obviously a safer alternative. The fact that such a particle is commercially available today is astonishing. This could be a very important step forward for a number of promising clinical methods.”

Dr Catherine J. Murphy

Gold nanorod pioneer, professor of chemistry, Department of Chemistry, University of Illinois

“Sona’s unique gold nanotechnology is very impressive and has the potential to transform lateral flow. We are proud to partner with such an innovative company and we know that together Sona and Bond can achieve great things.”

Phil Groom

Commercial Director, Bond Digital Health

Upcoming events

Meet members of Team Sona and learn more about our technology, products and services at these upcoming events:

• Advanced Lateral Flow Course, 22-24 October 2019, San Diego, CA, USA

To arrange a meeting or learn more, get in touch.

CONTACT US

Latest News

Sona Nanotech Engages Maxim Group for NASDAQ Listing and Investment Banking Services, and Announces Organizational Change

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (“Sona Nanotech” or the “Company”), a developer of rapid, point-of-care diagnostic tests for COVID-19 and other applications, has engaged Maxim Group, LLC (“Maxim”) for general financial advisory and investment banking services in relation to its planned application to list the Company’s common shares on the NASDAQ Capital Market (“NASDAQ”). By up-listing to NASDAQ, the Company aspires to gain new exposure and access to a larger base of retail and institutional investors in the United States and internationally. The Company believes that the NASDAQ is the world’s pre-eminent exchange for biotechnology and related companies.

Read More »
July 8, 2020
SONA NEWS

Latest Blog Post
Blog

The lateral flow market in 2020

The worldwide lateral flow market is large, and growing rapidly, with more than 2 billion tests produced every year. Worth an estimated $6 billion (US) in 2018, the market is projected to reach $8.7 billion (US) in 2023. In this blog Sona CEO Darren Rowles takes a look at the market and what 2020 might bring.   What is the current state of the market and how might this change in 2020?   Whichever market segment you look at, for example human health, animal health or agriculture, lateral flow is an in-demand technology. Professionals working in these sectors want quick

Read More »
November 28, 2019
SONA BLOG
Sona_Nanotech_Logo_H
Subscribe to the Sona Newsletter
Linkedin-in Twitter Youtube Instagram Facebook

Privacy Policy